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Abstract
Background: Chronic rhinosinusitis (CRS) is a chronic inflammatory disease associ-
ated with a substantial personal and socioeconomic burden. Monitoring of patient-
reported outcomes by mobile technology offers the possibility to better understand 
real-life burden of CRS.
Methods: This study reports on the cross-sectional evaluation of data of 626 users of 
mySinusitisCoach (mSC), a mobile application for CRS patients. Patient characteristics 
of mSC users were analysed as well as the level of disease control based on VAS global 
rhinosinusitis symptom score and adapted EPOS criteria.
Results: The mSC cohort represents a heterogeneous group of CRS patients with a 
diverse pattern of major symptoms. Approximately half of patients reported nasal 
polyps. 47.3% of all CRS patients were uncontrolled based on evaluation of VAS 
global rhinosinusitis symptom score compared to 40.9% based on adapted EPOS cri-
teria. The impact of CRS on sleep quality and daily life activities was significantly 
higher in uncontrolled versus well-controlled patients. Half of patients had a history 
of FESS (functional endoscopic sinus surgery) and reported lower symptom severity 
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1  | INTRODUC TION
Chronic rhinosinusitis (CRS) is defined as a chronic inflammatory dis-
order of the nose and paranasal sinuses.1,2 The clinical presentation 
consists of an impaired sense of smell, facial pain or pressure, post-
nasal drip, rhinorrhoea and/or nasal congestion for a consecutive 
period of at least 12 weeks.1 CRS affects 10.9% of the European 
citizens according to population-bases studies and is associated 
with a significant socioeconomic burden.3,4 CRS can be divided 
into two major subtypes: with (CRSwNP) or without (CRSsNP) nasal 
polyps.5 Sinonasal type 2 inflammation is found in the majority of 
European CRSwNP patients.6 Although CRS patients frequently re-
port co-morbidities such as asthma and allergic rhinitis, it is unclear 
if a causal relationship between atopy and CRS truly exists.7,8 In a 
study of almost 600 patients, more severe asthma was found to be 
associated with a more severe CRS with allergic sensitization and/
or nasal polyps.9
The cornerstone of CRS treatment includes saline rinsing and 
anti-inflammatory treatment with prolonged topical or short-course 
oral corticosteroids.1 Functional endoscopic sinus surgery (FESS) is 
recommended in case of failure of maximal pharmaceutical treat-
ment. Nonetheless, a substantial percentage of CRS patients still ex-
periences bothersome symptoms interfering with daily life despite 
standard pharmaceutical and surgical therapy.10 According to EPOS 
guidelines, uncontrolled disease is defined by the presence of three 
or more of the following features: nasal blockage, anterior or poste-
rior nasal secretions, facial pain, impaired sense of smell and sleep 
disturbance or fatigue; in addition to signs of diseased sinonasal 
compared to patients without a history of FESS, except for patients with a history of 
more than 3 procedures. Patients with a history of FESS reported higher VAS levels 
for impaired smell.
Conclusion: Real-life data confirm the high disease burden in uncontrolled CRS 
patients, clearly impacting quality of life. Sinus surgery improves patient-reported 
outcomes, but not in patients with a history of more than 3 procedures. Mobile tech-
nology opens a new era of real-life monitoring, supporting the evolution of care to-
wards precision medicine.
K E Y W O R D S
Mobile health technology, nasal polyp, patient-reported outcome measure, real-world 
evidence, visual analogue scale
G R A P H I C A L  A B S T R A C T
This study reports on the cross-sectional evaluation of patient-reported outcome measures in 626 chronic rhinosinusitis patients of which 
half reported nasal polyp disease. Over 40% of patients were uncontrolled, which clearly impacted their quality of life. Sinus surgery 
improved patient-reported outcomes, but not in patients with a history of more than 3 procedures.
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mucosa and/or need of long-term antibiotics or systemic corticoste-
roids in the past 1-3 months.1 Forty per cent of patients were found 
to be uncontrolled despite pharmaceutical and surgical treatment in 
a tertiary referral centre.11
Mobile health (mHealth) applications are emerging as novel tools 
for self-management in chronic respiratory diseases (CRDs).12 Apps 
aim to reinforce patient empowerment by monitoring disease activ-
ity, education, personalised messaging and feedback, and facilitating 
interaction between the patient and the healthcare provider. This 
engagement may improve medication adherence, health outcomes 
as well as quality of life. Moreover, the mHealth applications offer 
the possibility of repeated and remote monitoring of the patients’ 
disease status, simultaneously collecting large sets of real-life data 
on patient-reported outcome measures.13
Recently, a mobile application (app) that enables self-monitoring 
and patient education, called mySinusitisCoach (mSC), was launched 
by a consortium of medical experts dealing with CRDs, united by the 
European Forum for Research and Education in Allergy and Airway 
Diseases (EUFOREA).14 Similar to the MACVIA Allergy Diary app for 
patients with allergic rhinitis,13 a visual analogue scale (VAS) is used 
to assess the level of disease control. The use of VAS on smartphone 
screens was validated to assess allergic rhinitis symptoms and disease 
control.15
In this study, we report on the cross-sectional evaluation of 
baseline data of 626 users of mSC. We recorded the profile of pa-




The app could be freely downloaded from the 2 most common digital 
distribution platforms (Apple App Store and Google Play Store) and 
was available in 3 countries (Belgium, the Netherlands and United 
Kingdom). The app was promoted via various national scientific 
meetings of ENT doctors as well as flyers and posters in the waiting 
rooms of the outpatient clinic of both academic and non-academic 
centres. Patients were considered for use of the mSC application 
when they filled out to have 2 or more sinonasal symptoms and/
or to have a doctor-based diagnosis of CRS. The mobile application 
was recommended to be used for better follow-up and increased 
patient empowerment of CRS patients. All mSC users (n = 626) who 
completed the RhinoSinusitis Diary14 between 10 November 2017 
and 2 April 2019 were included in the study.
2.2 | Ethical aspects
The Terms of Use and Privacy Statement, available in the local lan-
guage, allow the use of the results for research purposes. An institu-
tional review board (IRB) approval was not required.
2.3 | Patient profile
The following patients' characteristics were collected in the patient 
profile of mSC: demographic characteristics (year of birth, gender, 
country, language), smoking status, presence of co-morbidities (al-
lergic rhinitis or AR, asthma, chronic obstructive pulmonary disease 
or COPD) and disease-related factors (presence of nasal polyps and 
history of functional endoscopic sinus surgery or FESS). Country-
specific medication for nose, eyes and lungs was recorded.
2.4 | Patient outcomes
Information on general and specific CRS symptoms (impaired smell, 
facial pain or pressure, postnasal drip, nasal secretions and nasal 
blockage) was obtained using a VAS score (0-100 mm),14 which has 
been previously validated for use on smartphone screens.15 The 
major symptom was defined as the CRS symptom with the highest 
VAS score. In addition, three additional questions addressed the im-
pact of CRS on sleep quality, lower airway symptoms and daily life 
activities as described earlier.14 A usability test was performed with 
a limited number of patients to evaluate the ease to complete the 
Health Diary as part of the registration process of the app as medical 
device class I. Patients were able to complete the health diary mul-
tiple times per day. The last recorded values for the respective day 
were used for analysis.
2.5 | Assessment of disease control
The level of disease control assessed by the patient in the mSC app 
was based on the VAS global sinusitis symptom score, which cor-
relates with SinoNasal Outcome Test-22 (SNOT-22) scores.16 The 
following cut-off levels were applied: controlled (VAS ≤ 20 mm), 
partly controlled (VAS >20 mm and ≤50 mm) and uncontrolled (VAS 
>50 mm and ≤100 mm). Alternatively, disease control was defined 
based on the adapted EPOS criteria for comparison in Figure 1 only. 
Five characteristics (nasal blockage, rhinorrhoea/postnasal drip, fa-
cial pain, impaired sense of smell and sleep disturbance or fatigue) are 
deemed critical to determine the level of disease control according 
to EPOS guidelines: controlled (no symptoms present), partly con-
trolled (presence of at least one symptom) or uncontrolled (presence 
of 3 or more symptoms). Clinical signs of inflammation and medica-
tion history were not taken into account. For the current study, a 
VAS level higher than 50 mm was used to define the presence of one 
of the respective symptoms.
2.6 | Evaluation of app use
The number of times the app has been used was defined as the sum 
of days that the user completed the VAS for global rhinosinusitis 
symptoms. The time span over which the app was used was defined 
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as the number of days between the first and the last time of use. The 
patients were advised to use the app on a weekly base. Reminders to 
complete the health diary were fixed on “weekly” by default to en-
sure continued data input. Longitudinal patient-reported data were 
not included in the current report.
2.7 | Statistics
Statistical analyses were performed with GraphPad Prism VI for 
Macintosh (GraphPad Software Inc, San Diego, USA) by use of 
Kruskal-Wallis, Dunn's multiple comparison test (as post-test) and 
Mann-Whitney U test when appropriate. Chi-square test was used 
to compare proportions between groups. Normality was analysed 
prior to between-group analysis by Shapiro-Wilk test. t test was per-
formed if data were normally distributed. A difference was consid-
ered to be significant when P < .05.
3  | RESULTS
3.1 | Patient profile
Table 1 summarises the patient characteristics of the mSC users. An 
equal proportion of men (308; 49.2%) and women (318; 50.8%) used 
the app, with a mean age of 43.9 ± 13.4 years. A detailed age distri-
bution histogram is shown in Figure S1. The app was used on aver-
age 8, 9 and 16 times by, respectively, controlled, partly controlled 
and uncontrolled patients over a mean period of 9 weeks (data not 
shown).
Approximately half of the CRS population, 282 patients (51.8%), 
reported physician-diagnosed nasal polyps (unknown in 82 subjects). 
Three hundred twenty-six patients (52.1%) reported to currently 
take pharmaceutical treatment (nasal corticosteroids (INS), oral 
corticosteroids (OCS), antibiotics or inhaled corticosteroids (ICS), 
anti-histamine or leukotriene receptor antagonist). In total, 327 
F I G U R E  1   Evaluation of disease control and impact of sinusitis symptoms on sleep quality and daily life activities. A. The level of disease 
control was defined by VAS global sinusitis symptom score: controlled (VAS ≤ 20 mm), partly controlled (VAS > 20 mm and ≤ 50 mm) and 
uncontrolled (VAS > 50 mm and ≤ 100 mm). B. Disease control was assessed by evaluation of 5 characteristics (nasal blockage, rhinorrhoea/
postnasal drip, facial pain or pressure, impaired sense of smell and sleep disturbance or fatigue) that are deemed critical to determine the 
level of disease control according to EPOS guidelines: controlled (no symptoms present), partly controlled (presence of one symptom) or 
uncontrolled (presence of 3 or more symptoms). A VAS level higher than 50 mm defined the presence of one of the respective symptoms. 
C. The impact of the patients’ rhinosinusitis symptoms on sleep quality and daily life activities were evaluated by VAS: “How much are 
your sinusitis symptoms affecting your sleep quality?” and “How much are your sinusitis symptoms affecting your work and daily activities 
today?” Data are presented as median with interquartile range. Three groups of CRS patients stratified by disease control were compared 
by use of Kruskal-Wallis test and Dunn's multiple comparison test (as post hoc test). ****: P < .0001 compared to controlled, #: P < .0001 
compared to partly controlled
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patients (52.2%) reported a history of FESS (1 FESS: 200 patients, 
2 FESS: 69 patients, 3 FESS: 34 patients, >3 FESS: 24 patients). Co-
morbidities such as allergic rhinitis, asthma and COPD were reported 
in, respectively, 284 (48.2%), 174 (32.2%) and 33 (5.9%) of patients.
3.2 | Burden of uncontrolled disease
Upon patient assessment of the level of disease control by the VAS 
global rhinosinusitis symptom score, 47.3% of patients were identi-
fied with uncontrolled disease versus 23.3% and 29.4% of patients 
with partly controlled and well-controlled disease, respectively 
(Figure 1A). No major differences were observed in patient profile 
characteristics among the three groups (Table 1). CRS patients with 
uncontrolled disease show higher median VAS for the impact of 
CRS symptoms on sleep quality as well as daily life activities com-
pared to the partly controlled and controlled patients (Figure 1C and 
Supplementary Table S1). All specific symptoms were significantly 
higher in partly controlled (P < .0001) and uncontrolled (P < .0001) 
patients compared to controlled patients (Supplementary Table S2).
Alternatively, when the adapted EPOS criteria for disease con-
trol were applied, 40.9% of patients were defined as uncontrolled 
compared to 33.9% and 25.2% of patients with partly controlled and 
well-controlled disease, respectively (Figure 1B).
3.3 | CRSwNP versus CRSsNP
CRS patients with nasal polyps (CRSwNP) reported higher 








626 146 (23.3%) 184 (29.4%) 296(47.3%)
Age, years 
(mean ± SD)
43.9 ± 13.4 43.8 ± 14.1 44.2 ± 14.4 43.8 ± 12.5 .95
Male/female 308/318 73/76 88/95 147/147 .92
Chronic rhinosinusitis
sNP 48.2% 44.9% 48.4% 49.6% .68




45.2% 39.9% 44.8% 43.5% .54
Oral 
corticosteroids
4.2% 4.4% 2.7% 4.4% .46
Antibiotics 3.4% 3.8% 3.8% 2.3% .40
Inhaled 
corticosteroids
15.5% 17.4% 16.9% 13.6% .47
Sinus surgery
Primary 31.9% 34.9% 29.5% 32.0% .58
Revision 20.3% 20.8% 19.1% 20.7% .90
Allergic rhinitisb  48.2% 54.6% 44.8% 47.1% .20
Asthmac 
Childhood onset 8.5% 9.8% 8.8% 7.3% .76
Adulthood onset 23.7% 24.1% 21.3% 23.9% .71
COPDd  5.9% 9.0% 6.0% 4.3% .17
Smoking status
Current smoker 11.8% 11.4 9.8% 13.3% .52
Ex-smoker 18.6% 18.8% 20.8% 17.0% .59
Never smoker 69.6% 69.8% 69.4% 69.7% 1.00
aUnknown in 82 patients. 
bUnknown in 37 patients. 
cUnknown in 86 patients. 
dUnknown in 67 patients. 
*Comparison between controlled, partly controlled and uncontrolled groups. 
TA B L E  1   Patient characteristics of 
mySinusitisCoach users
     |  7SEYS Et al.
polyps (CRSsNP) (P < .0001), whereas CRSsNP showed higher VAS 
scores for facial pain compared to CRSwNP (P < .0001) (Figure 2, 
Supplementary Table S3). Median VAS for major symptom was sig-
nificantly higher in patients with CRSwNP compared to CRSsNP. 
Impaired sense of smell was the most bothersome symptom re-
ported by both CRSwNP and CRSsNP (Figure 3). Almost half of 
CRSwNP patients reported impaired sense of smell as most both-
ersome symptom (Figure 3).
3.4 | Asthma co-morbidity
Self-reported asthma was significantly higher in CRSwNP (42.2%) 
compared to CRSsNP (16.5%; P < .0001; Figure 4A). Median VAS 
bronchial symptoms (data from 176 patients) were significantly 
higher in uncontrolled compared to partly controlled (P < .05) and 
controlled (P < .0001) CRS patients (Figure 4B). No significant differ-
ences in global and specific CRS symptoms were observed between 
CRS patients with or without asthma (data not shown).
3.5 | Impact of treatment on CRS symptoms
3.5.1 | Surgical treatment
Figure 5 shows the VAS score for global and specific CRS symptoms 
in patients stratified by the number of FESS procedures. Global 
rhinosinusitis symptoms as well as facial pain, nasal blockage and 
nasal secretions were lower in patient with a history of FESS (1, 2, 
3 procedures) compared to patients without a history of FESS. In 
contrast, patients with a history of FESS reported higher levels of 
impaired sense of smell compared to patients without history of 
FESS (P = .003). Interestingly, patients with a history of more than 3 
FESS procedures showed the highest level of symptoms, exceeding 
levels of poor control seen in patients without a history of FESS. The 
symptom that contributed most to uncontrolled disease in these pa-
tients was again impaired sense of smell (Supplementary Figure S2E). 
The proportion of patients with a history of FESS was significantly 
higher in CRSwNP (66.0%) compared to CRSsNP (20.6%) patients 
(P < .0001; Supplementary Table S4). Analysis of the impact of FESS 
on global and specific CRS symptoms in CRSwNP patients showed 
similar tendencies as in the full CRS patient cohort (Supplementary 
Figure S3A-B).
3.5.2 | Pharmaceutical treatment
More than half of the CRS patients reported taking pharmaceutical 
treatment, that is INS (45.2%), OCS (4.2%), antibiotics (3.4%) and/or 
ICS (15.5%) (Table 1). Global rhinosinusitis symptoms were not signif-
icantly lower in patients who reported taking INS (P25-median-P75: 
20 - 48 - 68) compared to those who did not report taking INS (P25-
median-P75: 29- 52 - 70). The subgroups of patients taking OCS, 
antibiotics or ICS were too small to perform an adequate analysis.
4  | DISCUSSION
This study is the first of its kind providing real-life data of CRS 
patients using mHealth technology. Here we report on the cross-
sectional analysis of data from 626 users of mSC in Belgium, The 
Netherlands and United Kingdom. Forty-seven per cent of CRS pa-
tients were classified as uncontrolled based on self-evaluation of 
VAS for global sinusitis symptoms. Uncontrolled patients reported 
a significantly higher impact of CRS symptoms on sleep quality and 
daily life activities compared to patients with well-controlled disease 
underlining the impact of CRS on different aspects of patient's qual-
ity of life.
F I G U R E  2   Comparison of global and specific rhinosinusitis symptoms between CRSsNP and CRSwNP phenotypes. Global rhinosinusitis 
symptoms were assessed by VAS: “How much are your global sinusitis symptoms bothering you today?”. Major symptom was defined as the 
most bothersome (highest VAS score) specific CRS symptom. Data are presented as median with interquartile range (missing information on 
NP status in 82 patients). Mann-Whitney U test was used for in-between group comparison. **: P < .01, ****: P < .0001
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Achieving or maintaining optimal disease control is key in the 
decision-making process of CRS management. EPOS guideline de-
fines disease control by the presence of 5 cardinal symptoms with 
or without endoscopic signs of infection and the need for systemic 
therapies.1 However, so far, no validated tools or questionnaires are 
however available to assess CRS disease control in real life. SNOT-
22 is the best-established validated CRS questionnaire to assess the 
impact of CRS on quality of life. Recently, an association between 
SNOT-22 and VAS global rhinosinusitis symptoms score was demon-
strated,16 pointing towards the usefulness of a simple VAS based 
score to monitor patients with CRS. The use of VAS has previously 
been validated to assess disease control in patients with allergic rhi-
nitis using the MACVIA Allergy Diary app.15
The proportion of patients who were identified with uncon-
trolled disease in the current analysis is in line with previous real-life 
reports. We here demonstrated that 296 patients (47.3%) are uncon-
trolled by use of VAS global rhinosinusitis symptoms compared to 
256 patients (40.9%) by use of adapted EPOS criteria. EPOS defini-
tion of disease control could however not be entirely assessed given 
the lack of information on signs of infection and need for systemic 
therapies. A previous study using the EPOS criteria to assess dis-
ease control showed that 40% of CRS patients were uncontrolled 
despite pharmaceutical and surgical treatment in a tertiary centre.11 
One might however argue that the use of mHealth technology to as-
sess disease control is likely to be biased towards those patients with 
uncontrolled disease. In that respect, we showed that uncontrolled 
patients are using mSC over a longer period of time than well-con-
trolled patients. In addition, patients with uncontrolled disease may 
be overrepresented in the current cohort because of preferential ad-
vertisement of mSC in tertiary centres. Nevertheless, our cross-sec-
tional data on disease control seem to mirror previous real-life data.
Furthermore, the patients were advised to use the app on a 
weekly base. Our results showed that patients with controlled or 
partly controlled CRS followed this advice. Patients with uncon-
trolled disease doubled the frequency of completing the health 
diary, which likely reflects the presence of increased symptoms.
We anticipated that patients with a younger age profile would 
be overrepresented within the mSC cohort. However, we found age 
ranges that equal those that have been reported previously.6,17 This 
indicates the willingness of older CRS patients to use mHealth tech-
nology to monitor their symptoms and also suggests that the mSC 
app is easy to use for patients across different age groups.
A considerable amount of literature has been published demon-
strating an association between asthma and CRS, especially with 
the CRSwNP phenotype.7,8,18 We show here that 32.2% patients re-
ported a physician-based diagnosis of asthma. This proportion of pa-
tients corresponds with previous studies evaluating the prevalence 
of asthma in CRS patients in tertiary centres,8 but is higher than a 
recent report showing concomitant asthma in 16.3% of CRS patients 
in a population-based study.18 The higher proportion of patients 
F I G U R E  3   Analysis of the major 
symptom between CRSsNP and CRSwNP 
phenotypes. The proportion of patients 
with a particular major symptom was 
compared between CRSsNP and CRSwNP. 
Major symptom was defined as the most 
bothersome (highest VAS score) specific 
CRS symptom. Missing information on NP 
status in 82 patients
F I G U R E  4   Prevalence of self-reported asthma (A) and burden of bronchial symptoms (B) in mSC users. A. Information on self-reported 
asthma was extracted from the health profile of mSC users. B. Bronchial symptoms were assessed by VAS: “How much is shortness of 
breath or wheezing bothering you today?”. Data are presented as median with interquartile range. Three groups of CRS patients stratified by 
disease control were compared by use of Kruskal-Wallis test and Dunn's multiple comparison test (as post hoc test). *: P < .05 compared to 
controlled, ****: P < .0001 compared to controlled, #: P < .01 compared to partly controlled
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with late-onset compared to early-onset asthma in our cohort con-
firms previous studies.7 In our study, allergic rhinitis was reported as 
a co-morbidity in 48.2% of CRS patients, which is in line with other 
studies demonstrating skin prick test positivity in up to half of CRS 
patients.8
A low level of adherence to pharmaceutical treatment was ob-
served without differences depending on the level of disease control 
of the patients. This could be due to patients who experienced side 
effects of corticosteroids, corticofobia or underreporting in the app 
by the patient.
FESS is a treatment option for CRS patients with uncontrolled 
disease despite pharmaceutical treatment.19 Managing nasal polyps 
in CRSwNP patients remains a therapeutic challenge with recur-
rence rates at 1 year after FESS of 38% and at 12 years after surgery 
in up to 78.9% of patients.20,21 In the latter study, revision surgery 
took place in 36.8% of patients over the 12-year period.20 Our study 
showed that 20.3% of CRS patients had a history of revision surgery. 
With every consecutive FESS procedure, VAS for both global and 
the majority of specific CRS symptoms declined. However, for a sub-
group of patients with a history of more than three surgeries (n = 16), 
VAS for global and specific CRS symptoms was equally high or even 
higher compared to patients without a history of sinus surgery. In 
this subgroup, additional surgery will likely not further improve 
disease control, underlining the need for alternative treatment op-
tions. On a short-term, however, evidence suggests that there is a 
temporarily beneficial effect of revision surgery but that the interval 
between successive operations becomes shorter.22
On the other hand, impaired sense of smell seemed to be unre-
sponsive to FESS treatment, possibly indicating the fact that sinus 
surgery typically spares the olfactory cleft. The lack of beneficial 
effect of revision FESS could also be explained by several other rea-
sons. Firstly, patients with more severe CRSwNP and hence more 
rapid recurrence of nasal polyps might not benefit very much from 
endoscopic sinus surgery. The research group of Peter Hellings 
already reported in Allergy on uncontrolled CRSwNP after sinus 
surgery in 80% of aspirin-intolerant CRSwNP patients.11 Secondly, 
FESS in the olfactory area may be associated with scar formation, 
preventing smell improvement to occur even after nasal polyp re-
moval. It is generally accepted by the sinus surgery community that 
scarification and/or direct injury to the olfactory nerve might occur 
after or during sinus surgery, respectively. Thirdly, the subgroup of 
patients with a higher number of FESS procedures are likely to be 
enriched by more severe CRS patients who are characterized by 
increased severity of smell impairment. Other studies have shown 
short-term relief of both objective and subjective olfactory mea-
surements.23 However, cross-sectional analysis of hyposmia and 
F I G U R E  5   Evaluation of global and specific rhinosinusitis symptoms in CRS patients stratified by the number of functional endoscopic 
sinus surgery (FESS) procedures. Information on the number of FESS procedures was extracted from the health profile of mSC users. Five 
groups of CRS patients stratified by the number of FESS procedures were compared by use of Kruskal-Wallis test and Dunn's multiple 
comparison test (as post hoc test). **: P < .01 compared to 0 FESS procedures
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anosmia prevalence showed rates ranging from 60% to 70%.24 In line 
with this, impaired sense of smell was the most bothersome symp-
tom reported by mSC users. This points at the significance of routine 
olfactory testing in patients with CRS in order to characterize olfac-
tory loss in a more detailed way.25
For the refractory subgroup of CRSwNP patients, biologic treat-
ment that is currently being investigated for patients with nasal 
polyps may be an alternative treatment approach.26-29 Based on the 
favourable clinical outcomes of phase II-III clinical trials as well as the 
high unmet need among CRSwNP patients, criteria for biologic ther-
apy have been developed by a multidisciplinary expert team united 
by EUFOREA aiming to provide a framework for implementation of 
biologics in clinical practice for CRSwNP patients.30
Collecting real-life data through mobile technology has several 
advantages over existing disease registries.31-33 It allows longitudi-
nal collection of patient-reported outcome measures that are usually 
not present in electronic health records, thereby being complemen-
tary to other real-life registries. Additionally, well-adopted mHealth 
applications allow longitudinal data collection in a wide variety of 
centres as well as at different levels of healthcare delivery. When 
analysing real-life data from mHealth applications, one should, how-
ever, be aware of a potential bias towards specific profiles of patients 
that are more keen on or familiar with using mHealth technology as 
well as bias because of the self-reported nature of the data. Also, 
the fact that patients did not complete the health diary on fixed 
days may have introduced a certain degree of bias but is inherent 
to the real-life nature of the implementation of such technology for 
at-home patient follow up. However, this study only reports on pa-
tients with a full record of the patient-reported outcome measures 
and does not include any longitudinal data. Lastly, we acknowledge 
that saline irrigations were not included as a treatment option in the 
mSC application.
In order to optimally meet the needs of patients and healthcare 
providers, mSC has been updated and upgraded with a series of ad-
ditional functionalities in combination with a physician dashboard to 
be used in the outpatient clinic, now called Galenus Health. Such 
improvements will further support the adoption of e-health support 
of patients with asthma, rhinitis and chronic rhinosinusitis.
In conclusion, this real-life study confirms the high burden of 
uncontrolled disease in CRS patients, which clearly impacts daily 
functioning of CRS patients. Sinus surgery improves patient-re-
ported outcomes, but not in patients with a history of more than 
3 procedures. Mobile technology opens a new era of real-life stud-
ies, which supports the evolution towards preventive and predictive 
medicine.34,35
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